COMMUNIQUÉS West-GlobeNewswire

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26/07/2019
BOTHELL, Wash., July 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
priMED Medical Products Appoints Lucas Ethier as Executive Vice President
26/07/2019
Company fortifies its commitment to market growth, product focus and worldwide expansion EDMONTON, Alberta, Canada, July 26, 2019 (GLOBE NEWSWIRE) -- priMED Medical Products Inc. (priMED), a global medical product [...]
Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer
26/07/2019
Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer PARIS – July 26, 2019 – Following Olivier Brandicourt’s decision to claim his pension rights as of September 1, 2019, the Board of [...]
Sanofi : Information sur les conditions de départ d’Olivier Brandicourt, Directeur Général
26/07/2019
Information sur les conditions de départ d’Olivier Brandicourt, Directeur Général PARIS – 26 juillet 2019 – Faisant suite à la décision d’Olivier Brandicourt de faire valoir ses droits à la retraite à compter du 1 er [...]
CROSSJECT : Résultats des votes de l'Assemblée Générale Mixte du 20 juin 2019
26/07/2019
Communiqué de Presse Crossject : Résultats des votes de l’Assemblée Générale Mixte du 20 juin 2019 Dijon, le 26 Juillet 2019 L’assemblée générale mixte des actionnaires de CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ [...]
Abeona Therapeutics annonce des données intermédiaires positives provenant de l'essai clinique de phase 1/2 sur la thérapie génique ABO-102 dans la MPS III A
26/07/2019
Développement neurocognitif des patients les plus jeunes conservé 12 à 18 mois après le traitement ; les scores de développement restent dans la fourchette des enfants non affectés Amélioration solide et durable des [...]
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
26/07/2019
Orphazyme A/S Company announcement No. 19/2019 Company Registration No. 32266355 Copenhagen, July 26, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients [...]
Avinger to Announce Second Quarter 2019 Financial Results on July 31, 2019
26/07/2019
REDWOOD CITY, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for [...]
Generex Biotechnology Provides a Summary of Its Investor Conference Call Held on July 25, 2019
26/07/2019
Filing up-list application to Nasdaq Details on 1:1 Shareholder stock dividend Spin-out of NuGenerex Immuno-Oncology as a separately-traded public company Merger of NGIO with Kiromic Payoff of notes Recording available [...]
SeaSpine Announces 20,000th NanoMetalene® Implantation
26/07/2019
CARLSBAD, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]
Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness
26/07/2019
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Phase III RAINBOW trial [...]
Avid Bioservices Announces Appointment of Catherine Mackey, Ph.D. to Board of Directors
26/07/2019
TUSTIN, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by [...]
Operational Update
26/07/2019
TACTI-002 patient recruitment update Three patients now enrolled and dosed in INSIGHT-004, recruitment ongoing Significant eftilagimod alpha clinical data expected in coming months: º AIPAC Phase II - first data [...]
Theratechnologies Receives Positive Recommendation From the CHMP for Trogarzo® in the European Union
26/07/2019
MONTREAL, July 26, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Committee for Medicinal Products for Human use (CHMP) in Europe has given a positive [...]
Theratechnologies reçoit une recommandation positive du CHMP pour le Trogarzo(MD) dans l’Union européenne
26/07/2019
MONTRÉAL, 26 juill. 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que le Comité des médicaments à usage humain (CHMP) en Europe a émis une recommandation positive [...]
T2 Biosystems Expands Global Access to its Innovative Rapid Diagnostic Technologies
26/07/2019
Company enters exclusive distribution agreements covering five new markets: Estonia, Greece, Ireland, Saudi Arabia and South Africa LEXINGTON, Mass., July 26, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), [...]
Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors
26/07/2019
CAMBRIDGE, Mass., July 26, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that it has entered into a securities purchase agreement with a select group of institutional investors and [...]
Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
26/07/2019
Decision based on data showing that the Tecentriq plus chemotherapy combination demonstrated a significant overall survival (OS) and progression-free survival (PFS) benefit in the first-line treatment of people with [...]
CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
26/07/2019
Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years Basel, 26 July 2019 [...]

Pages